PHILADELPHIA — (Aug. 25, 2021) — According to a study by The Wistar Institute, the tumor suppressor Parkin, whose levels are reduced in different cancer types, causes acute metabolic and oxidative st…
PHILADELPHIA — (Aug. 17, 2021) — The Wistar Institute announces that the National Institutes of Health (NIH) granted a five-year, $29.15 million Martin Delaney Collaboratories for HIV Cure Research a…
PHILADELPHIA — (July 30, 2021) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of Daniel Claiborne, Ph.D…
PHILADELPHIA — (July 20, 2021) — Alternative polyadenylation (APA) is an RNA processing mechanism that regulates gene expression by generating different ends on RNA transcripts of the same gene. Thou…
PHILADELPHIA — (June 29, 2021) — New biomarkers that predict HIV remission after antiretroviral therapy (ART) interruption are critical for the development of new therapeutic strategies that can achi…
PHILADELPHIA — (June 2, 2021) — The Wistar Institute, an international biomedical research leader with special expertise in cancer, immunology and infectious disease research and vaccine development…
PHILADELPHIA — (June 1, 2021) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of Noam Auslander, Ph.D., as…
PHILADELPHIA – May 20, 2021 – The Wistar Institute has partnered with doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers to issue a joint statement urg…
PHILADELPHIA and MELBOURNE, Australia — (May. 17, 2021) — A team of scientists from The Wistar Institute in Philadelphia and the Peter MacCallum Cancer Center in Melbourne, Australia, discovered a ne…
PHILADELPHIA — (April 27, 2021) — The Wistar Institute and the University of Bologna (Unibo) in Italy have established the Wistar-Unibo Ph.D. Exchange Program in Cell and Molecular Biology to bring U…
